LONDON–(BUSINESS WIRE)–Oct 7, 2020–
The global allergy immunotherapies market size is poised to grow by USD 626.77 million during 2020-2024, progressing at a CAGR of about 7% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005629/en/
Technavio has announced its latest market research report titled Global Allergy Immunotherapies Market 2020-2024 (Graphic: Business Wire).
The increasing prevalence of allergies is driving the need for allergy immunotherapies. Allergies are regarded as one of the most common ailments, affecting more than 500 million people around the world. The rising incidence of allergy is triggered by factors such as the growing pollution and increased consumption of tobacco products like cigarettes. Moreover, a large portion of people are affected multiple times due to the non-remissive nature of the allergy. The huge unmet need for allergy treatment globally has led to various vendors conducting research on novel therapies, resulting in advances in the field of immunology therapeutics for allergies.
Register for a free trial today and gain instant access to 17,000+ market research reports.Technavio’s SUBSCRIPTION platform
Report Highlights:
- The major allergy immunotherapies market growth came from SCIT segment. It was the largest product segment of the allergy immunotherapies market in 2019, mainly because of the high efficiency for the treatment of various respiratory allergies. Additionally, SCITs are administered in simple and standardized doses, and they result in long-lasting symptom relief. Thus, contributing to the growth of the market in focus.
- Europe had the largest allergy immunotherapies market share in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The high prevalence of allergies will significantly influence allergy immunotherapies market growth in this region.
- The global allergy immunotherapies market is concentrated. Aimmune Therapeutics Inc., ALK-Abelló AS, Allergy Therapeutics Plc, ASIT Biotech SA, DBV Technologies SA, HAL Allergy BV, Jubilant Life Sciences Ltd., Laboratorios LETI SLU, Merck KGaA, and Stallergenes Greer Plc. are some of the major market participants. To help clients improve their market position, this allergy immunotherapies market forecast report provides a detailed analysis of the market leaders.
- As the business impact of COVID-19 spreads, the global allergy immunotherapies market 2020-2024 is expected to have Neutral and At par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Read the full report here:https://www.technavio.com/report/report/allergy-immunotherapies-market-industry-analysis
Presence of a Strong Pipeline for Allergy Immunotherapy and the Estimated New Approvals will be a Key Market Trend
The strong efficacy and relatively higher safety of allergy immunotherapies combined with a strong prevalence of various allergies create an attractive opportunity for the market players. Hence, several pharmaceutical and biotechnology companies have started conducting research on the development of immunotherapies for the treatment of various allergies, such as house dust mite allergies, grass pollen-induced allergic rhinitis, and ragweed pollen allergy. Additionally, vendors are conducting extensive R&D resulting in a strong pipeline for unaddressed indications such as peanut allergy. For instance, AR101 is a SLIT under development by Aimmune Therapeutics, which is in Phase III of clinical trials. Hence, the presence of a strong pipeline for allergy immunotherapy and the estimated new approvals are expected to contribute to the market growth during the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report
Allergy Immunotherapies Market 2020-2024: Key Highlights
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will assist allergy immunotherapies market growth during the next five years
- Estimation of the allergy immunotherapies market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the allergy immunotherapies market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of allergy immunotherapies market vendors
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 – 2024
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product placement
- SCIT – Market size and forecast 2019-2024
- SLIT – Market size and forecast 2019-2024
- Market opportunity by Product
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- Europe – Market size and forecast 2019-2024
- North America – Market size and forecast 2019-2024
- APAC – Market size and forecast 2019-2024
- MEA – Market size and forecast 2019-2024
- South America – Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
Drivers, Challenges, and Trends
- Market drivers
- Volume driver – Demand led growth
- Volume driver – Supply led growth
- Volume driver – External factors
- Volume driver – Demand shift in adjacent markets
- Price driver – Inflation
- Price driver – Shift from lower to higher-priced units
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Aimmune Therapeutics Inc.
- ALK-Abelló AS
- Allergy Therapeutics Plc
- ASIT Biotech SA
- DBV Technologies SA
- HAL Allergy BV
- Jubilant Life Sciences Ltd.
- Laboratorios LETI SLU
- Merck KGaA
- Stallergenes Greer Plc
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20201007005629/en/
CONTACT: Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website:www.technavio.com/
KEYWORD:
INDUSTRY KEYWORD: GENERAL HEALTH PHARMACEUTICAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2020.
PUB: 10/07/2020 08:45 PM/DISC: 10/07/2020 08:45 PM
Copyright Business Wire 2020.
